RECRUITING

OMAR Opioid Use Disorder

Talk to us

Conditions

Healthy ControlOpioid Use Disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

Official Title

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

Quick Facts

Study Start:2023-03-10
Study Completion:2025-12-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05683184

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Able to provide informed consent
  2. * Male and female 18 years and older
  3. * DSM-5 diagnosis of opioid use disorder (for OUD group)
  4. * Physically healthy i.e., no clinically unstable medical conditions
  5. * Written informed consent and have capacity to consent and comply with study procedures
  1. * Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).
  2. * Presence of ferromagnetic metal in the body or heart pacemaker
  3. * Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits
  4. * Are claustrophobic

Contacts and Locations

Study Contact

Anahita Bassir Nia, MD
CONTACT
203-974-7540
anahita.bassirnia@yale.edu
Angelina Contreras
CONTACT
203-626-1105
angelina.contreras@yale.edu

Principal Investigator

Anahita Bassir Nia, MD
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

Connecticut Mental Health Center, Clinical Neuroscience Research Unit
New Haven, Connecticut, 06519
United States

Collaborators and Investigators

Sponsor: Yale University

  • Anahita Bassir Nia, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-10
Study Completion Date2025-12-15

Study Record Updates

Study Start Date2023-03-10
Study Completion Date2025-12-15

Terms related to this study

Additional Relevant MeSH Terms

  • Healthy Control
  • Opioid Use Disorder